|
1
|
Collins MH, Zhao H, Womer RB and Barr FG:
Proliferative and apoptotic differences between alveolar
rhabdomyosarcoma subtypes: A comparative study of tumors containing
PAX3-FKHR or PAX7-FKHR gene fusions. Med Pediatr Oncol. 37:83–89.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sandberg AA, Stone JF, Czarnecki L and
Cohen JD: Hematologic masquerade of rhabdomyosarcoma. Am J Hematol.
68:51–57. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Davis RJ, D'Cruz CM, Lovell MA, Biegel JA
and Barr FG: Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14)
translocation in alveolar rhabdomyosarcoma. Cancer Res.
54:2869–2872. 1994.PubMed/NCBI
|
|
4
|
Schneider G, Bowser MJ, Shin DM, Barr FG
and Ratajczak MZ: The paternally imprinted DLK1-GTL2 locus is
differentially methylated in embryonal and alveolar
rhabdomyosarcomas. Int J Oncol. 44:295–300. 2014.
|
|
5
|
Liang K, Esteva FJ, Albarracin C,
Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, et
al: Recombinant human erythropoietin antagonizes trastuzumab
treatment of breast cancer cells via Jak2-mediated Src activation
and PTEN inactivation. Cancer Cell. 18:423–435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Todaro M, Turdo A, Bartucci M, Iovino F,
Dattilo R, Biffoni M, Stassi G, Federici G, De Maria R and Zeuner
A: Erythropoietin activates cell survival pathways in breast cancer
stem-like cells to protect them from chemotherapy. Cancer Res.
73:6393–6400. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Trost N, Stepisnik T, Berne S, Pucer A,
Petan T, Komel R and Debeljak N: Recombinant human erythropoietin
alters gene expression and stimulates proliferation of MCF-7 breast
cancer cells. Radiol Oncol. 47:382–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Morais C, Johnson DW, Vesey DA and Gobe
GC: Functional significance of erythropoietin in renal cell
carcinoma. BMC Cancer. 13:142013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seibold ND, Schild SE, Gebhard MP, Noack
F, Schröder U and Rades D: Prognosis of patients with locally
advanced squamous cell carcinoma of the head and neck. Impact of
tumor cell expression of EPO and EPO-R. Strahlenther Onkol.
189:559–565. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang L, Li HG, Xia ZS, Wen JM and Lv J:
Prognostic significance of erythropoietin and erythropoietin
receptor in gastric adenocarcinoma. World J Gastroenterol.
17:3933–3940. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumar SM, Zhang G, Bastian BC, Arcasoy MO,
Karande P, Pushparajan A, Acs G and Xu X: Erythropoietin receptor
contributes to melanoma cell survival in vivo. Oncogene.
31:1649–1660. 2012. View Article : Google Scholar :
|
|
12
|
Lopez TV, Lappin TR, Maxwell P, Shi Z,
Lopez-Marure R, Aguilar C and Rocha-Zavaleta L: Autocrine/paracrine
erythropoietin signalling promotes JAK/STAT-dependent proliferation
of human cervical cancer cells. Int J Cancer. 129:2566–2576. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aguilar C, Aguilar C, Lopez-Marure R,
Jiménez-Sánchez A and Rocha-Zavaleta L: Co-stimulation with stem
cell factor and erythropoietin enhances migration of c-Kit
expressing cervical cancer cells through the sustained activation
of ERK1/2. Mol Med Rep. 9:1895–1902. 2014.PubMed/NCBI
|
|
14
|
Batra S, Perelman N, Luck LR, Shimada H
and Malik P: Pediatric tumor cells express erythropoietin and a
functional erythropoietin receptor that promotes angiogenesis and
tumor cell survival. Lab Invest. 83:1477–1487. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suszynska M, Poniewierska-Baran A, Gunjal
P, Ratajczak J, Marycz K, Kakar SS, Kucia M and Ratajczak MZ:
Expression of the erythropoietin receptor by germline-derived cells
- further support for a potential developmental link between the
germline and hematopoiesis. J Ovarian Res. 7:662014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jacobs JF, Brasseur F, Hulsbergen-van de
Kaa CA, van de Rakt MW, Figdor CG, Adema GJ, Hoogerbrugge PM,
Coulie PG and de Vries IJ: Cancer-germline gene expression in
pediatric solid tumors using quantitative real-time PCR. Int J
Cancer. 120:67–74. 2007. View Article : Google Scholar
|
|
17
|
Virchow R: Archiv fuer pathologische
anatomie und physiologie und fuer klinische. Medizin. 8:23–54.
1855.(In German).
|
|
18
|
Conheim J: Congenitales, quergestreiftes
Muskelsarkon der Nireren. Virchows Arch. 65:64–69. 1875.(In
German). View Article : Google Scholar
|
|
19
|
Aloisio GM, Nakada Y, Saatcioglu HD, Peña
CG, Baker MD, Tarnawa ED, Mukherjee J, Manjunath H, Bugde A,
Sengupta AL, et al: PAX7 expression defines germline stem cells in
the adult testis. J Clin Invest. 124:3929–3944. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grymula K, Tarnowski M, Wysoczynski M,
Drukala J, Barr FG, Ratajczak J, Kucia M and Ratajczak MZ:
Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1
axes in regulating metastatic behavior of human rhabdomyosarcomas.
Int J Cancer. 127:2554–2568. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rölfing JH, Baatrup A, Stiehler M, Jensen
J, Lysdahl H and Bünger C: The osteogenic effect of erythropoietin
on human mesenchymal stromal cells is dose-dependent and involves
non-hematopoietic receptors and multiple intracellular signaling
pathways. Stem Cell Rev. 10:69–78. 2014. View Article : Google Scholar
|
|
22
|
Broxmeyer HE: Erythropoietin: Multiple
targets, actions, and modifying influences for biological and
clinical consideration. J Exp Med. 210:205–208. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Libura J, Drukala J, Majka M, Tomescu O,
Navenot JM, Kucia M, Marquez L, Peiper SC, Barr FG,
Janowska-Wieczorek A, et al: CXCR4-SDF-1 signaling is active in
rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and
adhesion. Blood. 100:2597–2606. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jankowski K, Kucia M, Wysoczynski M, Reca
R, Zhao D, Trzyna E, Trent J, Peiper S, Zembala M, Ratajczak J, et
al: Both hepatocyte growth factor (HGF) and stromal-derived
factor-1 regulate the metastatic behavior of human rhabdomyosarcoma
cells, but only HGF enhances their resistance to radiochemotherapy.
Cancer Res. 63:7926–7935. 2003.PubMed/NCBI
|
|
25
|
Kang MH, Smith MA, Morton CL, Keshelava N,
Houghton PJ and Reynolds CP: National Cancer Institute pediatric
preclinical testing program: Model description for in vitro
cytotoxicity testing. Pediatr Blood Cancer. 56:239–249. 2011.
View Article : Google Scholar
|
|
26
|
Maxwell P, Melendez-Rodríguez F, Matchett
KB, Aragones J, Ben-Califa N, Jaekel H, Hengst L, Lindner H,
Bernardini A, Brockmeier U, et al: Novel antibodies directed
against the human erythropoietin receptor: Creating a basis for
clinical implementation. Br J Haematol. 168:429–442. 2015.
View Article : Google Scholar
|
|
27
|
Stolze I, Berchner-Pfannschmidt U, Freitag
P, Wotzlaw C, Rössler J, Frede S, Acker H and Fandrey J:
Hypoxia-inducible erythropoietin gene expression in human
neuroblastoma cells. Blood. 100:2623–2628. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ribatti D, Poliani PL, Longo V, Mangieri
D, Nico B and Vacca A: Erythropoietin/erythropoietin receptor
system is involved in angiogenesis in human neuroblastoma.
Histopathology. 50:636–641. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sartelet H, Fabre M, Castaing M, Bosq J,
Racu I, Lagonotte E, Scott V, Lecluse Y, Barette S, Michiels S, et
al: Expression of erythropoietin and its receptor in
neuroblastomas. Cancer. 110:1096–1106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tarnowski M, Grymula K, Reca R, Jankowski
K, Maksym R, Tarnowska J, Przybylski G, Barr FG, Kucia M and
Ratajczak MZ: Regulation of expression of stromal-derived factor-1
receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. Mol Cancer
Res. 8:1–14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tarnowski M, Grymula K, Liu R, Tarnowska
J, Drukala J, Ratajczak J, Mitchell RA, Ratajczak MZ and Kucia M:
Macrophage migration inhibitory factor is secreted by
rhabdomyosarcoma cells, modulates tumor metastasis by binding to
CXCR4 and CXCR7 receptors and inhibits recruitment of
cancer-associated fibroblasts. Mol Cancer Res. 8:1328–1343. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wysoczynski M, Miekus K, Jankowski K,
Wanzeck J, Bertolone S, Janowska-Wieczorek A, Ratajczak J and
Ratajczak MZ: Leukemia inhibitory factor: A newly identified
metastatic factor in rhabdomyosarcomas. Cancer Res. 67:2131–2140.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schneider G, Bryndza E, Abdel-Latif A,
Ratajczak J, Maj M, Tarnowski M, Klyachkin YM, Houghton P, Morris
AJ, Vater A, et al: Bioactive lipids S1P and C1P are prometastatic
factors in human rhabdomyosarcoma, and their tissue levels increase
in response to radio/chemotherapy. Mol Cancer Res. 11:793–807.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schneider G, Sellers ZP, Abdel-Latif A,
Morris AJ and Ratajczak MZ: Bioactive lipids, LPC and LPA, are
novel prometastatic factors and their tissue levels increase in
response to radio/chemotherapy. Mol Cancer Res. 12:1560–1573. 2014.
View Article : Google Scholar : PubMed/NCBI
|
